Evidence map›Paper›PMID 41993306›Full record

ArticlebioRxiv : the preprint server for biology2026

Transcriptional and spatial profiling of fibroblasts from human lungs highlights CTHRC1+ cells as fibrogenic signaling hubs in fibrosis.

N D Vanegas-Avendano, H Chen, J Wellmerling, J Rodriguez-Lopez, A Ghobashi, V Peters, C Sen, B F Reader, K Shilo, B Gomperts and 4 more

Abstract readPreprint
In one paragraph

Article in bioRxiv : the preprint server for biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

N D Vanegas-AvendanoDivision of Pulmonary, Critical Care, & Sleep Medicine, Department of Internal Medicine, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
H ChenDivision of Pulmonary, Critical Care, & Sleep Medicine, Department of Internal Medicine, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
J WellmerlingDepartment of Physiology & Biomedical Engineering. Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
J Rodriguez-LopezDivision of Pulmonary, Critical Care, & Sleep Medicine, Department of Internal Medicine, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
A GhobashiDivision of Pulmonary, Critical Care, & Sleep Medicine, Department of Internal Medicine, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
V PetersDivision of Pulmonary, Critical Care, & Sleep Medicine, Department of Internal Medicine, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
C SenChildren's Discovery and Innovation Institute, Broad StemCell Research Center, Jonsson Comprehensive Cancer Center, Departments of Pediatrics and Pulmonary Medicine, University of California, Los Angeles, California, USA.
B F ReaderHuman Tissue Biorepository. OSU Wexner Medical Center Comprehensive Transplant Center, The Ohio State University, Columbus, OH, USA.
K ShiloDepartment of Pathology, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
B GompertsChildren's Discovery and Innovation Institute, Broad StemCell Research Center, Jonsson Comprehensive Cancer Center, Departments of Pediatrics and Pulmonary Medicine, University of California, Los Angeles, California, USA.
Q MaDepartment of Biomedical Informatics, College of Medicine, The Ohio State University, Columbus, OH, USA.
A L MoraDivision of Pulmonary, Critical Care, & Sleep Medicine, Department of Internal Medicine, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.
D J TschumperlinDepartment of Physiology & Biomedical Engineering. Mayo Clinic College of Medicine and Science, Rochester, Minnesota, USA.
M RojasDivision of Pulmonary, Critical Care, & Sleep Medicine, Department of Internal Medicine, The Ohio State University, Wexner Medical Center, Columbus, OH, USA.

Funding

XenograftP30CA046592 · NCI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI Eric R. Fearon · 1988 to 2026
$178.2M
TriState SenNET (Lung and Heart) Tissue Map and Atlas consortiumU54AG075931 · NIA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI TOREN FINKEL, Melanie Koenigshoff · 2021 to 2026
$14.0M
Fibrogenic activation and memory in the lung mesenchymeR01HL166187 · NHLBI · MAYO CLINIC ROCHESTER · PI Daniel J. Tschumperlin · 2023 to 2026
$2.4M
Therapeutic ECM Resorption in Cellular Systems and Precision Cut Lung Slices.U01HL152967 · NHLBI · MAYO CLINIC ROCHESTER · PI TSCHUMPERLIN, DANIEL J. · 2021 to 2024
$2.4M
NCI NIH HHS P30 CA046592NHLBI NIH HHS R01 HL166187NHLBI NIH HHS U01 HL152967NIA NIH HHS U54 AG075931
6 · The paper itself

Abstract

Lung fibroblasts are key regulators of tissue homeostasis and extracellular matrix (ECM) remodeling, and their aberrant activation drives the progressive parenchymal scarring characteristic of idiopathic pulmonary fibrosis (IPF), a fatal disease with limited therapeutic options. Despite their central pathogenic role, lung fibroblasts are difficult to isolate due to their embedded position within the ECM, and standard in vitro culture conditions may lead to the loss of their native functional and transcriptional characteristics, hampering the study of fibroblast behavior in disease. The transcriptional heterogeneity of lung fibroblast subtypes and the extent to which culture-induced alterations diverge from native tissue signatures remain poorly understood. Here, we integrated single-cell RNA sequencing (scRNA-seq) and spatial transcriptomics of lung tissue from IPF patients and age-matched healthy donors with transcriptomic profiling of cultured fibroblasts collected at passages 1 and 6 after isolation using three optimized protocols: whole lung cell suspension (WLCS), negative fraction enrichment, and outgrowth. Tissue-based analysis identified six transcriptionally distinct mesenchymal subtypes: alveolar, adventitial, inflammatory, peribronchial, CTHRC1+ and smooth muscle cell (SMC). The fibroblast subtype CTHRC1+ represented the most transcriptionally activated pro-fibrotic subtype, showing the greatest upregulation of ECM biosynthesis genes, a prominent role in intercellular communication, and preferential enrichment within fibroblastic foci in IPF lung tissue. Pseudotime trajectory analysis supported a directional transcriptional continuum from alveolar and inflammatory fibroblasts toward the CTHRC1+ state, driven by coordinated activation of pro-fibrotic transcription factors, including RUNX2, CREB3L1, and SCX. In vitro culture progressively reshaped fibroblast transcriptional identity relative to native tissue, with increased collagen and matrix metalloproteinase (MMP) expression during passaging, loss of distinct CTHRC1+ fibroblasts, and gain of alveolar fibroblasts displaying pro-fibrotic activation across all isolation protocols. These findings provide a high-resolution transcriptional map of lung fibroblast heterogeneity in IPF and highlight critical limitations of standard in vitro culture systems for recapitulating native fibroblast diversity, with important implications for the development and evaluation of fibroblast-targeted therapeutic strategies in IPF.

Identifiers

PMID41993306
PMCPMC13081991

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.